Skip to main content
SpringerLink
Log in

Cancer and Cancer Treatment-Related Neuromuscular Disease

  • Chapter
Cancer Neurology in Clinical Practice

Abstract

Peripheral neuropathies distort the normal motor, sensory, and autonomic functions. Among the numerous causes are inherited disorders, entrapments, infections, toxins, nutritional deficiency states, and inflammatory, demyelinating, or ischemic conditions. Polyneuropathy is often a complication of systemic disease, such as diabetes, connective tissue disorders, or uremia. Neuropathy may also be a direct or remote effect of malignant disease. Compression by tumor or direct infiltration of nerve by malignant cells can cause radiculopathy, plexopathy, or mononeuropathy. Nonmetastatic or paraneoplastic neuropathy, a remote effect of cancer, occurs in 1% of all patients with malignancy. In addition, neuropathy may be a side effect of a therapeutic drug. In this review, we are concerned with neuromuscular conditions associated with malignant diseases or those caused by cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Olney RK. Clinical trials for polyneuropathy: the role of nerve conduction studies, quantitative sensory testing, and autonomic function testing. J Clin Neurophysiol 1998; 15: 129–137.

    Article  PubMed  CAS  Google Scholar 

  2. Quantitative sensory testing: a consensus report from the Peripheral Neuropathy Association. Neurology 1993; 43: 1050–1052.

    Google Scholar 

  3. Dyck PJ, Bushek W, Spring EM, Karnes JL, et al. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 1987; 10: 432–440.

    Article  PubMed  CAS  Google Scholar 

  4. Redmond JMT, McKenna ML. Quantitative sensory testing. Letters to the Editor. Muscle Nerve 1996: 403.

    Google Scholar 

  5. Lipton RB, Galer BS, Dutcher JP, Portenoy RK, et al. Larger and small type sensory dysfunction in patients with cancer. J Neurol Neurosurg Psychiatry 1991; 54: 706–709.

    Article  PubMed  CAS  Google Scholar 

  6. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced neuropathy with quantitative sensory testing. J Neuro Oncol 1997; 35: 4753.

    Article  Google Scholar 

  7. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996; 46: 108–111.

    Article  PubMed  CAS  Google Scholar 

  8. Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104–108.

    Article  PubMed  CAS  Google Scholar 

  9. Corbo M, Hays AP. Immunopathological studies in immune mediated neuropathies. In: Immunological and Infectious Diseases of the Peripheral Nerves. Latov N, Wokke JHJ, Kelly JJ Jr, eds. Cambridge University Press, Cambridge, UK, 1998, pp. 81–95.

    Google Scholar 

  10. Leung SF, Tsao SY, Teo P, Foo W. Cranial nerve involvement by nasopharyngeal carcinoma: response to treatment and clinical significance. Clin Oncol 1990; 2: 138–141.

    Article  CAS  Google Scholar 

  11. Gupta SR, Zdonczyk DE, Rubino FA. Cranial neuropathy in systemic malignancy in a VA population. Neurology 1990; 40: 997–999.

    Article  PubMed  CAS  Google Scholar 

  12. Burt RK, Sharfman WH, Karp BI, Wilson WH. Mental neuropathy (numb chin syndrome). A harbinger of tumor progression or relapse. Cancer 1992; 70: 877–881.

    Article  PubMed  CAS  Google Scholar 

  13. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathological study. Arch Neurol 1974; 30: 122.

    Article  PubMed  CAS  Google Scholar 

  14. Chad DA, Recht LD. Neuromuscular complications of systemic cancer. Neurol Clin 1991; 9: 901–918.

    PubMed  CAS  Google Scholar 

  15. Wilbourn AJ. Brachial plexus disorders. In: Peripheral Neuropathy. Dyck PJ, Thomas PK, eds. W.B. Saunders, Philadelphia, 1993, pp. 911–950.

    Google Scholar 

  16. Kori SH, Foley KM, Posner JB. Brachial plexus lesions in patients with cancer: 100 cases. Neurology 1981; 3: 45–50.

    Article  Google Scholar 

  17. Pancoast HK. Superior pulmonary sulcus tumor. JAMA 1932; 99: 1391–1396.

    Article  Google Scholar 

  18. Jaeckle KA, Young DF, Foley KM. The natural history of lumbosacral plexopathy in cancer. Neurology 1985; 35: 8–15.

    Article  PubMed  CAS  Google Scholar 

  19. Thomas JE, Cascino TL, Earle JD. Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology 1985; 35: 1–7.

    Article  PubMed  CAS  Google Scholar 

  20. Barron SA, Rowland LP, and Zimmermann H.M. Neuropathy with malignant tumor metastases. J Nery Ment Dis 1960; 131: 10–31.

    Article  CAS  Google Scholar 

  21. Rogers L.R., Borkowski G.P., Albers J.W., et al. Obturator mononeuropathy caused by pelvic cancer: six cases. Neurology 1993; 43: 1489–1492.

    Article  PubMed  CAS  Google Scholar 

  22. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948; 11: 73–87.

    Article  PubMed  CAS  Google Scholar 

  23. Wyburn-Mason R. Bronchial carcinoma presenting as a polyneuritis. Lancet 1948; 1: 203–215.

    Article  PubMed  CAS  Google Scholar 

  24. Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain 1965; 88: 449–456.

    Article  PubMed  CAS  Google Scholar 

  25. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 1992; 71: 59–72.

    Article  PubMed  CAS  Google Scholar 

  26. Posner JB, Furneaux HM. Paraneoplastic syndromes. In: Immunologic Mechanisms in Neurologic and Psychiatric Disease. Waksman BH, ed. Raven Press, New York, 1990, pp. 187–219.

    Google Scholar 

  27. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 1985; 35: 538–543.

    Article  PubMed  CAS  Google Scholar 

  28. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu-antigen (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141: 881–886.

    PubMed  CAS  Google Scholar 

  29. Lennon VA. Paraneoplastic autoantibodies: the case for a descriptive generic nomenclature. Neurology 1994; 44: 2236–2240.

    Article  PubMed  CAS  Google Scholar 

  30. Dalmau J, Furneaux HM, Rosemblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 1991; 41: 1757–1764.

    Article  PubMed  CAS  Google Scholar 

  31. Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Huassociated paraneoplastic encephalomyelitis. Neurology 1994; 44: 140–147.

    Article  PubMed  CAS  Google Scholar 

  32. Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996; 39: 659–667.

    Article  PubMed  CAS  Google Scholar 

  33. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndrome. J Neurol Neurosurg Psychiatry 1996; 61: 270–278.

    Article  PubMed  CAS  Google Scholar 

  34. Dropcho EJ. Neurologic paraneoplastic syndromes. J Neurologic Sci 1998; 153: 264–278.

    Article  CAS  Google Scholar 

  35. Wokke JHJ, van Dijk GW. Sensory neuropathies including painful and toxic neuropathies. J Neurol 1997; 244: 209–221.

    Article  PubMed  CAS  Google Scholar 

  36. Horwich MS, Cho L, Porro RS, Posner JB. Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol 1977; 2: 7–19.

    Article  PubMed  CAS  Google Scholar 

  37. Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 1992; 19: 346–351.

    PubMed  CAS  Google Scholar 

  38. Chalk CH, Lennon VA, Stevens JC, Windebank AJ. Seronegativity for type I antineuronal nuclear antibodies (“anti-Hu”) in subacute sensory neuronopathy patients without cancer. Neurology 1993; 43: 2209–2211.

    Article  PubMed  CAS  Google Scholar 

  39. Graus F, Bonaventura I, Uchuya M, et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994; 44: 2258–2261.

    Article  PubMed  CAS  Google Scholar 

  40. Fisher CM, Williams HW, Wing ES. Combined encephalopathy and neuropathy with carcinoma. J Neuropathol Exp Neurol 1961; 20: 535–542.

    Article  PubMed  CAS  Google Scholar 

  41. Evans CC, Kaufman HD. Unusual presentation of seminoma of the testis. Br J Surg 1971; 58: 703–708.

    Article  PubMed  CAS  Google Scholar 

  42. Klingon GH. The Guillain-Barre syndrome associated with cancer. Cancer 1965; 18: 157–163.

    Article  PubMed  CAS  Google Scholar 

  43. Graus F, Elkon KB, Lloberes P, et al. Neuronal antinuclear antibody (anti Hu) in paraneoplastic encephalomyelitis simulating acute polyneuritis. Acta Neurol 1987; 75: 249–252.

    Article  CAS  Google Scholar 

  44. Croft PB, Wilkinson M. The course and the prognosis in some types of carcinomatous neuromyopathy. Brain 1969; 92: 1–24.

    Article  PubMed  CAS  Google Scholar 

  45. Yamada M, Inaba A, Yamawaki M, et al. Paraneoplastic encephalo-myelo-ganglionitis: cellular binding sites of the antineuronal antibody. Acta Neuropathol 1994; 88: 85–92.

    Article  PubMed  CAS  Google Scholar 

  46. Croft PB, Urich H, Wilkinson M. Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain 1967; 90: 31–65.

    Article  PubMed  CAS  Google Scholar 

  47. Vincent D, Dubas F, Hauw JJ, et al. Nerve and muscle microvasculitis in peripheral neuropathy: a remote effect of cancer? J Neurol Neurosurg Psychiatry 1986; 49: 1007–1010.

    Article  PubMed  CAS  Google Scholar 

  48. Oh SJ, Slaughter R, Harrell L. Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Muscle Nerve 1991; 14: 151–156.

    Google Scholar 

  49. Matsumuro K, Izumo S, Umehara F, et al. Paraneoplastic vasculitis neuropathy: immunohistochemical studies on abiopsied nerve and post-mortem examination. J Intern Med 1994; 236: 225–230.

    Article  PubMed  CAS  Google Scholar 

  50. Ahmed MN, Carpenter S. Autonomic neuropathy and carcinoma of the lung. Can Med Assoc J 1975; 113: 410–412.

    PubMed  CAS  Google Scholar 

  51. Lhermitte F, Gray F, Lyon-Caen O, et al. Paralysis of digestive tract with lesions of myenteric plexus: a new paraneoplastic syndrome. Rev Neurol (Paris) 1980; 136: 825–836.

    CAS  Google Scholar 

  52. Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudo-obstruction with small cell lung carcinoma. Gastroenterology 1991; 100: 737–742.

    Google Scholar 

  53. Heidenreich F, Schober R, Brinck U, Hartung HP. Multiple paraneoplastic syndromes in a patient with antibodies to neuronal nucleoproteins (anti-Hu). J Neurol 1995; 242: 210–216.

    Article  PubMed  CAS  Google Scholar 

  54. Park DM, Johnson RH, Cream GP, Robinson JF. Orthostatic hypotension in bronchial carcinoma. BMJ 1972; 3: 510–511.

    Article  PubMed  CAS  Google Scholar 

  55. Liang BC, Albers JW, Sima AAF, Nostrant TT. Paraneoplastic pseudo-obstruction, mononeuropathy multiplex, and sensory neuronopathy. Muscle Nerve 1994; 17: 91–96.

    Article  PubMed  CAS  Google Scholar 

  56. Lachance DH, O’Neill BP, Harper CM, et al. Paraneoplastic brachial plexopathy in a patient with Hodgkin’s’s disease. Mayo Clin Proc 1991; 66: 97–101.

    Article  PubMed  CAS  Google Scholar 

  57. Hughes RAC, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J R Soc Med 1994; 87: 526–530.

    PubMed  CAS  Google Scholar 

  58. Currie S, Henson RA, Morgan HG, Poole AJ. The incidence of non-metastatic neurological syndromes of obscure origin in the reticuloses. Brain 1970; 93: 629–640.

    Article  PubMed  CAS  Google Scholar 

  59. Walsh JC. Neuropathy associated with lymphoma. J Neurol Neurosurg Psychiatry 1971; 34: 42.

    Article  PubMed  CAS  Google Scholar 

  60. Massachusetts General Hospital. Case records no. 8–1990. N Engl J Med 1990; 322: 531–543.

    Google Scholar 

  61. Plante-Bordeneuve V, Baudrimont M, Gorin NC, Gherardi RK. Subacute sensory neuropathy associated with Hodgkin’s disease. J Neurol Sci 1994; 121: 155–158.

    Article  PubMed  CAS  Google Scholar 

  62. Vallat JM, De Mascarel HA, Bordessoule D, et al. Non-Hodgkin malignant lymphomas and peripheral neuropathies-13 cases. Brain 1995; 118: 1233–1245.

    Article  PubMed  Google Scholar 

  63. Lisak RP, Mitchell M, Zweiman B, et al. Guillain-Barré syndrome and Hodgkin’s disease; three cases with immunological studies. Ann Neurol 1977; 1: 72–78.

    Article  PubMed  CAS  Google Scholar 

  64. Shoenfeld Y, Aderka D, Sandbank U, et al. Fatal peripheral neurolymphomatosis after remission of histiocytic lymphoma. Neurology 1983; 33: 243–245.

    Article  PubMed  CAS  Google Scholar 

  65. Moore RY, Oda Y. Malignant lymphomas with diffuse involvement of the peripheral nervous system. Neurology (Minneap) 1962; 12: 186–191.

    Article  CAS  Google Scholar 

  66. Gherardi R, Gaulard P, Prost C, et al. T-cell lymphoma revealed by a peripheral neuropathy. A report of two cases with an immunohistological study on lymph node and nerve biopsies. Cancer 1986; 58: 2710–2716.

    Article  PubMed  CAS  Google Scholar 

  67. Sumi SM, Farrell DF, Knauss TA. Lymphoma and leukemia manifested by steroid-responsive polyneuropathy. Arch Neurol 1983; 40: 577–582.

    Article  PubMed  CAS  Google Scholar 

  68. Rowland LP, Schneck SA. Neuromuscular disorders associated with malignant neoplastic disease. J Chronic Dis 1963; 16: 777–789.

    Article  PubMed  CAS  Google Scholar 

  69. Ince PJ, Shaw PJ, Fawcett PRW, Bates D. Demyelinating neuropathy due to primary IgM kappa B cell lymphoma of peripheral nerve. Neurology 1987; 37: 1231–1237.

    Article  PubMed  CAS  Google Scholar 

  70. Schold SC, Cho ES, Somasundaram M, and Posner JB. Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol 1979; 5: 271–287.

    Article  PubMed  CAS  Google Scholar 

  71. Younger DS, Rowland LP, Latov N, et al. Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol 1991; 29: 78–86.

    Article  PubMed  CAS  Google Scholar 

  72. Gordon P.H., Rowland L.P., Younger D.S., Sherman W.H., Hays A.P., Louis E.D., et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology 1997; 48: 1671–1678.

    Article  PubMed  CAS  Google Scholar 

  73. Rosenfeld MR, Posner JB. Paraneoplastic motor neuron disease. Adv Neurol 1991; 56: 445–459.

    PubMed  CAS  Google Scholar 

  74. Van Lieshout JJ, Wieling W, Van Montfrans GA, et al. Acute dysautonomia associated with Hodgkin’s disease. J Neurol Neurosurg Psychiatry 1986; 49: 830–832.

    Article  PubMed  Google Scholar 

  75. Turner ML, Boland OM, Parker AC, Ewing DJ. Subclinical autonomic dysfunction in patients with Hodgkin’s and non-Hodgkin’ s lymphoma. Br J Haematol 1993; 84: 623–626.

    Article  PubMed  CAS  Google Scholar 

  76. Wells CE, Silver RT, The neurologic manifestation of the acute leukemias: a clinical study. Ann Intern Med 1957; 46: 439–446.

    Article  PubMed  CAS  Google Scholar 

  77. Phanthumchinda K, Intragumtornchai T. Kasantikul V., Guillain- Barre syndrome and optic neuropathy in acute leukemia. Neurology 1988; 38: 1324–1328.

    Article  PubMed  CAS  Google Scholar 

  78. Krendel DA, Albright RE, Graham DG. Infiltrative polyneuropathy due to acute monoblastic leukemia in haematologic remission. Neurology 1987; 37: 474–482.

    Article  PubMed  CAS  Google Scholar 

  79. Haberland C, Cipriani M, Kucuk O, et al. Fulminant leukemic polyradiculoneuropathy in a case of B-cell promyelocytic leukemia. Cancer 1987; 60: 1454–1458.

    Article  PubMed  CAS  Google Scholar 

  80. Vital C, Bonnaud E, Arne L, et al. Polyneuritis in chronic lymphoid leukemia. Ultrastructural study of the peripheral nerve. Acta Neuropathol (Berl) 1975; 32: 169–176.

    Article  CAS  Google Scholar 

  81. Kuroda Y, Nakata H, Kakigi R, et al. Human lymphomatosis by adult T-cell leukemia. Neurology 1989; 39: 144–146.

    Article  PubMed  CAS  Google Scholar 

  82. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathy of undetermined significance. Ann Neurol 1991; 30: 54–61.

    Article  PubMed  CAS  Google Scholar 

  83. Yeung KB, Thomas PK, King RH, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol 1991; 238: 383–391.

    Article  PubMed  CAS  Google Scholar 

  84. Nobile-Orazio E, Vietorisz T, Messito MJ, et al. Anti-MAG IgM antibodies in patients with neuropathy and 1gM M proteins: detection by ELISA. Neurology 1983; 33: 939–942.

    Article  PubMed  CAS  Google Scholar 

  85. Hays AP, Lee SL, Latov N. Immunoreactive C3d on the surface of myelin sheaths in neurology. J Neuroimmunol 1988; 18: 231–244.

    Article  PubMed  CAS  Google Scholar 

  86. Vital C, Julien J, et al. Polyneuropathy associated with IgM monoclonal gammopathy; immunological and pathological study in 31 patients. Acta Neuropathol (Berl) 1989; 79: 160–167.

    Article  CAS  Google Scholar 

  87. Monaco S, Bonetti B, Ferrari S, et al. Complement dependent demyelination in patients with IgM monoclonal gammopathy. N Engl J Med 1990; 322: 844–852.

    Article  Google Scholar 

  88. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995; 37 (S1): S32 - S42.

    Article  PubMed  Google Scholar 

  89. Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin associated glycoprotein paraproteinemia. Ann Neurol 1988; 23: 304–396.

    Article  Google Scholar 

  90. Cook D, Dalakas M, Galdi A, et al. High dose intravenous immunoglobulins in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990; 40: 212–214.

    Article  PubMed  CAS  Google Scholar 

  91. Dellagi K, Dupounev P, Brouet JC, et al. Waldenstrom’s macroglobulinemia and peripheral neuropathy: a clinical and immunological study of 25 patients. Blood 1983; 62: 280–285.

    PubMed  CAS  Google Scholar 

  92. Diego Miralles G, O’Fallon JR, Talley NJ. Plasma cell dyscrasia with polyneuropathy. N Engl J Med 1992; 327: 1919–1923.

    Article  Google Scholar 

  93. Hesselvik M. Neuropathological studies on myelomatosis. Acta Neurol Scand 1969; 45: 95–108.

    Article  PubMed  CAS  Google Scholar 

  94. Kelly JJ Jr, Kyle RA, Miles JM, et al. The spectrum of peripheral neuropathy in myeloma. Neurology 1981; 31: 24–31.

    Article  PubMed  Google Scholar 

  95. Li K, Kyle RA, Dyck PJ. Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy. Am J Pathol 1992; 141: 217–226.

    PubMed  CAS  Google Scholar 

  96. Ohi T, Kyle RA, Dyck PJ. Axonal attenuation and secondary segmental demyelination in myeloma neuropathies. Ann Neurol 1985; 17: 255–261.

    Article  PubMed  CAS  Google Scholar 

  97. Verghese JP, Bradley WB, Nemni R, McAdam PWJ. Amyloid neuropathy in multiple myeloma and other plasma cell dyscrasias: a hypothesis of the pathogenesis of amyloid neuropathies. J Neurol Sci 1983; 59: 237–246.

    Article  PubMed  CAS  Google Scholar 

  98. Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine 1975; 54: 271–299.

    Article  PubMed  CAS  Google Scholar 

  99. Kelly JJ Jr, Kyle RA, Miles JM, Dyck PJ. Osteosclerotic myeloma and peripheral neuropathy. Neurology 1983; 33: 202–210.

    Article  PubMed  Google Scholar 

  100. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome, a study of 102 cases in Japan. Neurology 1984; 34: 712–720.

    Article  PubMed  CAS  Google Scholar 

  101. Kyle RA, Dyck PJ. Osteosclerotic myeloma (POEMS syndrome). In: Peripheral Neuropathy. Dyck PJ, Thomas PK, eds. W.B. Saunders, Philadelphia, 1993, 68, pp. 1288–1293.

    Google Scholar 

  102. Donofrio PD, Albers JW, Greenberg HS, Mitchell BS. Peripheral neuropathy in osteosclerotic myeloma: clinical and electrophysiologic improvement with chemotherapy. Muscle Nerve 1984; 7: 137–141.

    Article  PubMed  CAS  Google Scholar 

  103. Alexenian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484–486.

    Article  Google Scholar 

  104. Postma TJ, et al. Pitfalls in grading severity of chemotherapy-induced neuropathy. Ann Oncol 1998; 9: 739–744.

    Article  PubMed  CAS  Google Scholar 

  105. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146–153.

    PubMed  CAS  Google Scholar 

  106. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 1986; 4: 1295–1306.

    PubMed  CAS  Google Scholar 

  107. Longo DL, Duffey PL, DeVita VT, et al. Treatment of advanced stage Hodgkin’s disease: alternating noncrossresistant MOPP/ CABS is not superior to MOPP. J Clin Oncol 1991; 9: 1409–1420.

    PubMed  CAS  Google Scholar 

  108. Jackson DV, et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol 1985; 3: 1508–1512.

    PubMed  CAS  Google Scholar 

  109. Ratain MJ, et al. Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res 1986; 46: 48274830.

    Google Scholar 

  110. Jackson DV, Sethi VS, et al. Intravenous vincristine infusion: Phase I trial. Cancer 1981; 48: 2559–2564.

    Article  PubMed  Google Scholar 

  111. Jackson, DV, et al. Treatment of advanced non-Hodgkin’s lymphoma with vincristine infusion. Cancer 1984; 53: 2601–2606.

    Article  PubMed  Google Scholar 

  112. Casey EB, et al. Vicristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96: 69–86.

    Article  PubMed  CAS  Google Scholar 

  113. Van kooten B, et al. A pilot study on the influence of a corticotropin (4–9) analogue on vinca alkoloid-induced neuropathy. Arch Neurol 1992; 49: 1027–1031.

    Article  PubMed  Google Scholar 

  114. DeAngelis LM, et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin’ s lymphoma. Cancer 1991; 67: 2241–2246.

    Article  PubMed  CAS  Google Scholar 

  115. Rosenthal S, Kaufman S, Vincristine neurotoxicity. Ann Int Med 1974; 80: 733–737.

    Article  PubMed  CAS  Google Scholar 

  116. Stübgen JP, Neuromuscular disorders in systemic malignancy and its treatment. Muscle Nerve 1995; 18: 636–648.

    Article  PubMed  Google Scholar 

  117. Burns BV, et al. Vocal fold palsy following vinca alkaloid treatment. J Laryngol Otol 1998; 112: 485–487.

    Article  PubMed  CAS  Google Scholar 

  118. Sahek Z, Brady ST, et al. Studies on the pathogenesis of vincristine-induced neuropathy. Musle Nerve 1987; 10: 80–84.

    Article  Google Scholar 

  119. Vainionpää L, et al. Clinical neurological findings of children with acute lymphoblastic leukamia at diagnosis and during treatment. Eur J Pediatr 1993; 152: 115–119.

    Article  PubMed  Google Scholar 

  120. Reinders-Messelink HA, et al. Fine motor and hand writing problems after treatment for childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1996; 27: 551–555.

    Article  PubMed  CAS  Google Scholar 

  121. Hogan-Dann C, Fellmeth, WG, et al. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 1984; 252: 520–523.

    Article  Google Scholar 

  122. McGuire SA, et al. Acute vincrisitne neurotoxicity in the presence of hereditary motor and sensory neuropathy Type I. Med Pediatr Oncol 1989; 17: 520–523.

    Article  PubMed  CAS  Google Scholar 

  123. Olek MJ, et al. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis. JAOA 1999; 99 (3): 165–167.

    PubMed  CAS  Google Scholar 

  124. Bakshi N et al. Fulminant demyelinating neuropathy mimicking cerebral death. Muscle Nerve 1997; 20: 1595–1597.

    Article  PubMed  CAS  Google Scholar 

  125. Tanner KD, et al. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998; 395: 481–492.

    Article  PubMed  CAS  Google Scholar 

  126. Tanner KD, Reichling DB, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 1998; 18 (6): 6480–6491.

    PubMed  CAS  Google Scholar 

  127. Moress GR, et al. Neuropathy in lymphoblastic leukemia treated with vincristine. Arch Neurol 1967; 16: 377–384.

    Article  PubMed  CAS  Google Scholar 

  128. Gottschalk PG, et al. Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology 1968; 18: 875–882.

    Article  PubMed  CAS  Google Scholar 

  129. McLeod JG, et al. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1969; 32: 297–304.

    Article  PubMed  CAS  Google Scholar 

  130. Pace A, Bove L, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996; 61: 409–411.

    Article  PubMed  CAS  Google Scholar 

  131. Stübgen JP. Neuromuscular disorders in systemic malignancy. Curr Opin Neurol. 1996; 10: 371–375.

    Article  Google Scholar 

  132. Gelman KA, et al. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17 (2): 697–605.

    Google Scholar 

  133. Campana WM, et al. Prosaptide prevents paclitaxel neurotoxicity. NeuroToxicology 1998; 19 (2): 237–244.

    CAS  Google Scholar 

  134. Finley RS, Rowinsky EK. The management of paclitaxel-related toxicities. Ann Pharmacother 1994; 28: S27 - S30.

    PubMed  CAS  Google Scholar 

  135. Van Der Bent MJ, et al. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997; 20: 750–752.

    Article  PubMed  Google Scholar 

  136. Balmaceda C, Hesdorffer C, Lange D. Neurotoxicity associated with high-dose paclitaxel chemotherapy (abstract). Proc Am Soc Clin Oncol 1997; 16: 778.

    Google Scholar 

  137. Cliffer KD, et al. Physiological characterization of taxol induced large fiber sensory neuropathy in the rat. Ann Neurol 1998; 43: 46–55.

    Article  PubMed  CAS  Google Scholar 

  138. Rowinsky EK, et al. Neurotoxicity of taxol. Monogr Natl Cancer Inst 1993: 107–115.

    Google Scholar 

  139. Schaumburg HH, et al. Toxic neuropathies. Neurology 1979; 29: 429–431.

    Article  PubMed  CAS  Google Scholar 

  140. Sahenk Z, Barhon R, New P, Mendell JR. Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994; 51: 726–729.

    Article  PubMed  CAS  Google Scholar 

  141. Rowinsky EK, Jiroutek M, Bonomi P, et al. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin Clin Cancer Res 1999; 5: 767–774.

    CAS  Google Scholar 

  142. Hilkens, PHE, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104–108.

    Article  PubMed  CAS  Google Scholar 

  143. Hilkens PHE, et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (taxotere). Ann Oncol 1997; 8 (2): 187–190.

    Article  PubMed  CAS  Google Scholar 

  144. Hovestadt A, Van der Burg MEL. The course of neuropathy after cessation of cisplatin treatment, combined with ORG 2766 or placebo. J Neurol 1992; 239: 143–146.

    Article  PubMed  CAS  Google Scholar 

  145. Hilkens PHE, Planting AST, et al. Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur J Neurol 1994; 1: 45–50.

    Article  Google Scholar 

  146. New PZ, et al. Neurotoxicity of docetaxel (taxotere). Neurology 1996; 46: 108–111.

    Article  PubMed  CAS  Google Scholar 

  147. Freilich RJ, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115–118.

    Article  PubMed  CAS  Google Scholar 

  148. Hilkens PH, Pronk LC, et al. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997; 75 (3): 417–422.

    Article  PubMed  CAS  Google Scholar 

  149. Postma TJ, Vermorken JB, et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489–494.

    PubMed  CAS  Google Scholar 

  150. Roelofs RI, et al. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34: 934–938.

    Article  PubMed  CAS  Google Scholar 

  151. Gerristen van der Hoop RG, et al. Incidence of neuropathy in 365 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66: 1697–1702.

    Article  Google Scholar 

  152. Mollman JE, et al. Unusual presentation of cis-platinum neuropathy. Neurology 1988; 38: 488–490.

    Article  PubMed  CAS  Google Scholar 

  153. Heinzlef O, et al. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998; 64: 667–669.

    Article  PubMed  CAS  Google Scholar 

  154. Hansen SW, Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Dan Med Bull 1992; 39: 391–399.

    PubMed  CAS  Google Scholar 

  155. Cavaletti G, Bogliun G, et al. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 1994; 14: 1287–1292.

    PubMed  CAS  Google Scholar 

  156. Gill JS, Windenbank AJ. Cisplatin induced apoptosis in rat dorsal root ganglion neurons is associated with attempted into the cell cycle. J Clin Invest 1998; 101 (12): 2842–2850.

    Article  PubMed  CAS  Google Scholar 

  157. Thompson SW, et al. Cisplatin neuropathy, clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54: 1269–1275.

    Article  PubMed  CAS  Google Scholar 

  158. Mollman JE, Glover DJ, et al. Cisplatin neuropathy, risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61: 2192–2195.

    Article  PubMed  CAS  Google Scholar 

  159. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126–127.

    Article  PubMed  CAS  Google Scholar 

  160. ter Laak MP, et al. rhGCF2 Protects against cisplatin-induced neuropathy in the rat. J Neurosci Res 2000; 60: 237–244.

    Article  PubMed  Google Scholar 

  161. Apfel SC, et al. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Oncol 1992; 31: 78–60.

    Google Scholar 

  162. Meijer C, et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. NeuroToxicology 1999; 20 (6): 883–887.

    CAS  Google Scholar 

  163. Gregg RW, et al. Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795–803.

    PubMed  CAS  Google Scholar 

  164. Barajon I, Bersani M, et al. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuropathy. Exp Neurol 1996; 138: 93–104.

    Article  PubMed  CAS  Google Scholar 

  165. Caraceni A. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand 1997; 96: 260–261.

    Article  PubMed  CAS  Google Scholar 

  166. Alderson LM, Noonan PT, Sup Choi I, Henson JW. Regional subacute cranial neuropathies following internal carotid cisplatin infusion. Neurology 1996; 47: 1088–1090.

    Article  PubMed  CAS  Google Scholar 

  167. Kahn CE, Messersmith RN, Samuels BL. Brachial plexopathy as a complication of intraarterial cisplatin. Cardiovasc Intervent Radiol 1989; 12: 47–49.

    Article  PubMed  Google Scholar 

  168. Tutsch KD, et al. Phase I trial and pharmacokinetic study of ormaplatin. Proc Am Assoc Cancer Res 1992; 33: 536.

    Google Scholar 

  169. Bleiberg H. Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 1998; 77 (Suppl 4): 1–3.

    Article  PubMed  CAS  Google Scholar 

  170. Raymond E, Chaney SG, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053–1071.

    Article  PubMed  CAS  Google Scholar 

  171. Soulie P. Oxaliplatin: the first DACH platinum in clinical practice. Bull Cancer 1997; 84 (6): 665–673.

    PubMed  CAS  Google Scholar 

  172. Adams M, Kerby IJ, Rocker I, et al. on behalf of the Swons Gynaecological Cancer Group. A comparison of the toxicity and efficacy of cisplatin and carboplatin. Acta Oncol 1989; 1: 57–60.

    Article  Google Scholar 

  173. McKreage MJ. Comparative adverse effect profiles of platinum drugs. Drug Safety 1995; 12: 228–244.

    Article  Google Scholar 

  174. Cavaletti G, et al. Neuro-and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res 1998; 18: 3797–3802.

    PubMed  CAS  Google Scholar 

  175. Cavaletti G, Fabbrica D, et al. Carboplatin toxic effects of the peripheral nervous system of the rat. Ann Oncol 1998; 9: 443–447.

    Article  PubMed  CAS  Google Scholar 

  176. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999; 12: 565–571.

    Article  PubMed  CAS  Google Scholar 

  177. Heinzlef 0, et al. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998; 64: 667–669.

    Article  PubMed  CAS  Google Scholar 

  178. LaRoca RV, et al. Suramin-induced polyneuropathy. Neurology 1990; 40: 954–960.

    Article  Google Scholar 

  179. Chaudhry V, et al. A prospective study of suramin-induced peripheral neuropathy. Brain 1996; 119: 2039–2052.

    Article  PubMed  Google Scholar 

  180. Soliven B, et al. Evaluation of neuropathy in patients of suramin treatment. Muscle Nerve 1997; 20: 83–91.

    Article  PubMed  CAS  Google Scholar 

  181. Gill JS, Connolly DC, et al. Suramin induces phosphorylation of the high affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J Neurochem 1996; 66: 963–972.

    Article  PubMed  CAS  Google Scholar 

  182. Russell JW, et al. Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann Neurol 1994; 36: 221–228.

    Article  PubMed  CAS  Google Scholar 

  183. Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Diff 1998; 5: 876–883.

    Article  CAS  Google Scholar 

  184. Wiesner DA, et al. Programmed cell death in neurotumour cells involves the generation of ceramide. Glycoconjugate J 1996; 13: 327–333.

    Article  CAS  Google Scholar 

  185. Gill JS, Windebank AJ. Role of ceramide in suramin induced cancer cell death. Cancer Lett 1997; 119: 169–176.

    Article  PubMed  CAS  Google Scholar 

  186. Falkson G, et al. A clinical trial of the oral form of 4-demethylepipodophyllotoxin-d-ethyldiene glucoside. Cancer 1975; 35: 1141–1144.

    Article  PubMed  CAS  Google Scholar 

  187. Patel SR, et al. High-dose ifosfamide induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 1994; 86: 305–306.

    Article  PubMed  CAS  Google Scholar 

  188. Fine HA, Figg WD, Jaeckle K. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18 (4): 708–715.

    PubMed  CAS  Google Scholar 

  189. Hainsworth JD, Burris HA III, Erland JB, et al. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 1999; 85 (6): 1269–1276.

    Article  PubMed  CAS  Google Scholar 

  190. Hunter RE, Griffin TW, Stevens S, et al. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer. Cancer 1991; 68 (9): 1890–1894.

    Article  PubMed  CAS  Google Scholar 

  191. Perez EA, Hillman DW, Stella PJ, et al. A Phase II study of paclitaxel plus carboplatin’. as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; 88 (1): 124–131.

    Article  PubMed  CAS  Google Scholar 

  192. Ray-Coquard I, Biron I, Bachelot T, et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and/or paclitaxel-containing regimens. Cancer 1998; 82 (1): 134–140.

    Article  PubMed  CAS  Google Scholar 

  193. Grigg A, Szer J, Skov K, Barnett M. Multi-organ dysfunction associated with high-dose carboplatin therapy prior to autologous transplantation. Bone Marrow Transplant 1996; 17: 67–74.

    PubMed  CAS  Google Scholar 

  194. De Witt R, et al. Docetaxel (taxotere): an active agent in metastatic urothelial cancer: results of a Phase II study in nonchemotherapypretreated patients. Br J Cancer 1998; 78 (10): 1342–1345.

    Article  Google Scholar 

  195. Shapiro JD, Rothenberg ML, Sarosy GA, et al. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer 1998; 83 (9): 1980–1988.

    Article  PubMed  CAS  Google Scholar 

  196. Guastalla JP; Pujade-Luaraine E, Weber B, et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. Ann Oncol 1998; 9: 37–43.

    Article  PubMed  CAS  Google Scholar 

  197. Pagan O; Sessa C, Martinelli G, et al. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast carcinoma. Ann Oncol 1997; 8: 655–661.

    Article  Google Scholar 

  198. Nardi M, Aloe A, De Marci S; et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a Phase II study. Am J Clin Oncol 1997; 20 (3): 230–232.

    Article  PubMed  CAS  Google Scholar 

  199. Salter MM, Wheeler RH, Peters GE, et al. A Phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck. Am J Clin Oncol 1992; 15 (6): 461–463.

    Article  PubMed  CAS  Google Scholar 

  200. Felip E, Del Campo JM, Bodi R, et al. Cisplatin and vinorelbine followed by radiotherapy in the treatment of Stage III-B nonsmall cell lung carcinoma. Am J Clin Oncol 1997; 20 (4): 404–406.

    Article  PubMed  CAS  Google Scholar 

  201. Sarris AH, Hagemeister F, Romaguerra J, et al. Liposomal vincristine in relapsed non-Hodgkin’s lymphomas: early results of an ongoing Phase II trial. Ann Oncol 2000; 11: 69–72.

    Article  PubMed  CAS  Google Scholar 

  202. Soulie P, Bensmaine A, Garrino C, et al. Oxaliplatin/cisplatin (LOHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 1997; 33 (9): 1400–1406.

    Article  PubMed  CAS  Google Scholar 

  203. Hainsworth JD, Urba WJ, et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter, Phase II trial. Euro J Cancer 1998; 34 (5): 654–658.

    Article  CAS  Google Scholar 

  204. Simsek T, Uner M, Trak B, et al. Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas. (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). Eur J Gynaecol Oncol 1998; 19 (4): 405–407.

    PubMed  CAS  Google Scholar 

  205. Vandat LT, Papadopoulos K, Balmaceda C. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamaide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res 1998; 4: 1689–1695.

    Google Scholar 

  206. Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 1999; 39: 323–330.

    PubMed  CAS  Google Scholar 

  207. Dimopoulos MA, Papadimitriou CA, Georgoulias V, et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a Phase II multicenter dtudy. Gynecolog Oncol 2000; 78: 52–57.

    Article  CAS  Google Scholar 

  208. Shapiro F, Schneider J, Markman M, et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecolog Oncol 1997; 67: 39–45.

    Article  CAS  Google Scholar 

  209. Langer CJ, McAleer CA, Bonjo CA, et al. Paclitaxel by 1-h infusion in combination with carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). Euro J Cancer 2000; 36: 183–193.

    Article  CAS  Google Scholar 

  210. Eddy GL, Manetta A, Alvarez RD, et al. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysteroctomy and pelvic lymphadenectomy for FIGO Stage IB bulky cervical cancer: a gynecological oncology group pilot study. Gynecolog Oncol 1995; 57: 412–416.

    Article  CAS  Google Scholar 

  211. Elias AD, Wheeler C, Ayash LJ. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoetic stem cell support. Clin Cancer Res 1998; 4: 1443–1449.

    PubMed  CAS  Google Scholar 

  212. Berger T, Malayeri R, Doppelbauer A, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Euro J Cancer 1997; 33 (9): 1393–1399.

    Article  CAS  Google Scholar 

  213. Weintraub M, Adde MA, et al. Severe atypical neuropathy associated with adminisration of hemopoietic colonystimulating factors and vincristine. J Clin Oncol 1996; 14: 935–940.

    CAS  Google Scholar 

  214. Stübgen JP. Neuromuscular disorders in systemic malignancy. Curr Opin Neurol 1996; 10: 371–375.

    Article  Google Scholar 

  215. Mondrup K, Olsen NK, Pfeiffer P, Rose C. Clinical and electrodiagnostic findings in breast cancer patients with radiation-induced brachial plexus neuropathy. Acta Neurol Scand 1990; 81: 153.

    Article  PubMed  CAS  Google Scholar 

  216. Bagley FH, Walsh JW, Cady B, et al. Carcinomatous versus radiation-induced brachial plexus neuropathy in breast cancer. Cancer 1978; 41: 2154–2157.

    Article  PubMed  CAS  Google Scholar 

  217. Glass JP, Pettigrew LC, Maor M. Plexopathy induced by radiation therapy. Neurology 1985; 35: 1261–1265.

    Article  PubMed  CAS  Google Scholar 

  218. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, De Angelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115–118.

    Google Scholar 

  219. Rini BI, Gajewski TF. Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with thyoma treated with octreotide. Ann Oncol 1999; 10: 973–979.

    Article  PubMed  CAS  Google Scholar 

  220. Brown JM, et al. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Radiat Res 1990; 50: 7745–7749.

    CAS  Google Scholar 

  221. Gatzemeier, U., Rodriguez, G., et al., Tirapazamine–cisplatin: the synergy. Br J Cancer 1998; 77 (Suppl 4): 15–17.

    Article  PubMed  CAS  Google Scholar 

  222. Rusthoven JJ, Ahlgren P, Elhakim T, et al. Risk factors for varicella zoster disseminated infection among adult cancer patients with localized zoster. Cancer 1988; 62: 1641–1646.

    Article  PubMed  CAS  Google Scholar 

  223. Koehler PJ, Buscher M, Rozeman CA, Leffers P, Twijnstra A. Peroneal nerve neuropathy in cancer patients: a paraneoplastic syndrome? J Neurol 1997; 244: 328–332.

    Article  PubMed  CAS  Google Scholar 

  224. Namba T, Brunner NG, Grob D. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine 1978; 57: 411–433.

    Article  PubMed  CAS  Google Scholar 

  225. O’Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 1988; 111: 577–596.

    Article  PubMed  Google Scholar 

  226. Watkins SM, Griffin JP. High incidence of vincristine-induced neuropathy in lymphomas. BMJ 1978; 1: 610–612.

    Article  PubMed  CAS  Google Scholar 

  227. Weintraub M, Adde MA, Venzon DJ, et al. Severe atypical neur-opathy associated with administration of hematopoietic colony-stimulating growth factors and vincristine. J Clin Oncol 1996; 14: 935–940.

    PubMed  CAS  Google Scholar 

  228. McCunne JS, Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am J Health-Syst Pharm 1997; 54: 1755–1758.

    Google Scholar 

  229. Kaplan RS, Wiernik PH. Neurotoxicity of antineoplastic drugs. Sem Oncol 1982; 9: 103–130.

    CAS  Google Scholar 

  230. Schmalbruch H, Krarup C. Animal models of neuropathies. Baillieres Clin Neurol 1996; 5: 77–105.

    PubMed  CAS  Google Scholar 

  231. Twentyman PR. Modification by WR 2721 of the response to chemotherapy of tumors and normal tissues in the mouse. Br J Cancer 1983; 47: 57–63.

    Article  PubMed  CAS  Google Scholar 

  232. Kelland LR. New platinum antitumor complexes. Crit Rev OncolHemet 1993; 47: 57–63.

    Google Scholar 

  233. Contreras PC, et al. Insulin-like growth Factor-I prevents development of vincristine neuropathy in mice. Brain Res 1997; 774: 20–26.

    Article  PubMed  CAS  Google Scholar 

  234. Vandat LT, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001; 7: 1192–1197.

    Google Scholar 

  235. Johnson IS, et al. Antitumor principles derived from vinca rosea linn.I. vincaleukoblastine and leurosine. Cancer Res 1960; 20: 1016–1022.

    PubMed  CAS  Google Scholar 

  236. Boyle FM, Wheeler HR, Shenfield G. Glutomate ameliorates experimental vincristine neuropathy. J Pharm Exp Ther 1996; 279: 410–415.

    CAS  Google Scholar 

  237. Boyle FM, Monk R, et al. The experimental neuroprotectant glutamate does not inhibit cytotoxicity of vinca alkaloids, cisplatin or paclitaxel. Proc AACR (Abstract) 1997; 38: 607.

    Google Scholar 

  238. Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 1996; 279: 410–415.

    PubMed  CAS  Google Scholar 

  239. Pearce IA, et al. Glutamate acting on NMDA receptors stimulate neurite outgrowth from cerebellar granulate cells. FEBS Lett 1987; 223: 143–147.

    Article  PubMed  CAS  Google Scholar 

  240. Lipton SA, Rosenberg PA. Excitatory aminoacids as a final common pathway for neurological disorders. N Engl J Med 1994; 330: 613–622.

    Article  PubMed  CAS  Google Scholar 

  241. Roberts JA, Jenison EL, Kim KM, Clarke-Pearson D, Langleben A. A randomized, multicenter, double blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecolog Oncol 1997; 67: 172–177.

    Article  CAS  Google Scholar 

  242. Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, Elderson A, et al. An ACTH (4–9) analog prevents cisplatin-induced neuropathy in ovarian cancer patients. N Engl J Med 1990; 322: 89–94.

    Article  Google Scholar 

  243. Van Gerven JMA, Hovestadt A, Moll JWB, Rodenburg CJ, et al. The effects of an ACTH (4–9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 1994; 241: 432–435.

    Article  PubMed  Google Scholar 

  244. Helgren ME, et al. Neurotropin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy. J Neurosci 1997; 17 (1): 372–382.

    PubMed  CAS  Google Scholar 

  245. Wang Min-Sheng, et al. Pathogenisis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy. J Neuropath Exp Neurol 2000; 59 (7): 599–606.

    PubMed  CAS  Google Scholar 

  246. Cahn J. Nimodipine: Pharmacological and clinical properties. In: Proceedings I Nimotop Symposium, Munich. Betze, et al., eds. Schattauer, Stuggart 1985, pp. 137–140.

    Google Scholar 

  247. Hamers FPT, Gerritsen van der Hoop R, Traber J, Neijt JP, Jennekens FGI, Gispens WH. The calcium antagonist nimodipine in cisplatin induced neuropathy in the rat. Eur J Pharmacol 1990; 183: 1710–1711.

    Article  Google Scholar 

  248. Laak MP, et al. rhGGF2 protects against cisplatin-induced neuropathy in the rat. J Neurosci Res 2000; 60: 237–244.

    Article  PubMed  Google Scholar 

  249. Kemp G, et al. Amifostine pretreatment for protection against cyclophosphamide induced and cisplatin induced toxicities: results of randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101–2112.

    PubMed  CAS  Google Scholar 

  250. Spencer CM, et al. Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995; 50: 1001–1031.

    Article  PubMed  CAS  Google Scholar 

  251. Dellaflor-Weiss E, Blommaert F. Amifostine (WR 2721) protects from bone marrow toxicity of combinations of cisplatin and carboplatin without decreasing platinum-DNA adduct formation. Ann Oncol 1994; 5 (Suppl 5): 125.

    Google Scholar 

  252. Verstappen CCP, et al. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065. J NeuroOncol 1999; 44: 1–5.

    Article  PubMed  CAS  Google Scholar 

  253. Barde YA. The nerve growth factor family. Prog Growth Factor Res 1990; 2: 237–248.

    Article  PubMed  CAS  Google Scholar 

  254. Levi-Montalcini R. The nerve growth factor 35-years later. Science 1987; 237: 1154–1162.

    Article  PubMed  CAS  Google Scholar 

  255. De Santis S, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000; 6: 90–95.

    PubMed  Google Scholar 

  256. Hayakawa K, et al. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each other drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res 1998; 795: 313–319.

    Article  Google Scholar 

  257. Cho HE, Lowndes BD, et al. Neurotoxicology of vincristine in the cat. Arch Toxicol 1983; 52: 83–90.

    Article  PubMed  CAS  Google Scholar 

  258. Fiori MG, et al. Peripheral neuropathy induced by intravenous administration of vincristine sulfate in the rabbit. An intrastructural study. Toxicol Pathol 1995; 23: 248–255.

    Article  PubMed  CAS  Google Scholar 

  259. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol 1990; 25: 355–360.

    Article  PubMed  Google Scholar 

  260. Tredici G, et al. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J Neurooncol 1998; 36: 31–40.

    Article  PubMed  CAS  Google Scholar 

  261. Lewis ME, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993; 124: 73–88.

    Article  PubMed  CAS  Google Scholar 

  262. Ang LC., et al. Effects of astrocytes, insulin and insulin-like growth factor I on the survival of motoneurons in vitro. J Neurol Sci 1992; 109: 168–172.

    Article  PubMed  CAS  Google Scholar 

  263. Neff NT. Insulin-like growth factors: putative muscle derived trophic agents that promote motorneuron survival. J Neurobiol 1993; 24: 1578–1588.

    Article  PubMed  CAS  Google Scholar 

  264. Giddings CEM, et al. The influence of recombinant human insulin like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models. Cancer Chemother Pharmacol 2000; 45 (1): 21–30.

    Article  Google Scholar 

Download references

Authors
  1. Casilda Balmaceda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elina Korkin BS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Virginia Medical Center, Charlottesville, VA, USA

    David Schiff MD

  2. Center for Neuro-Oncology Dana-Farber Cancer Institute; and Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Patrick Y. Wen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Balmaceda, C., Korkin, E. (2003). Cancer and Cancer Treatment-Related Neuromuscular Disease. In: Schiff, D., Wen, P.Y. (eds) Cancer Neurology in Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-317-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-317-0_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4703-4

  • Online ISBN: 978-1-59259-317-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation